Jon Napitupulu

Apellis has secured a decisive evidence win for Empaveli (pegcetacoplan) in rare renal disease: the New England Journal of...

Amicus Therapeutics reported third-quarter 2025 revenue of $169.1 million, up 17% at constant exchange rates, and delivered GAAP net...

Plus Therapeutics reported three clinical updates for its targeted radiotherapeutic REYOBIQ (rhenium-186 obisbemeda) at the WFNOS/SNO annual meeting, underscoring...

ADMA Biologics reported third quarter 2025 revenue of $134.2 million, up 12% year over year, with GAAP net income...

EyePoint Pharmaceuticals has fully enrolled its two Phase 3 trials in wet age-related macular degeneration (LUGANO and LUCIA), initiated...

MoonLake Immunotherapeutics reported third-quarter 2025 results and a cascade of clinical updates that set up sonelokimab for a pivotal...

Inotiv reported fourth-quarter fiscal 2025 revenue of $138.1 million, up 5.9% year over year, and full-year revenue of $513.0...

BioCryst Pharmaceuticals received early termination of the Hart-Scott-Rodino waiting period for its proposed acquisition of Astria Therapeutics, clearing a...

OKYO Pharma’s executive chairman, through an affiliated entity, has increased his stake in the company by purchasing 27,051 additional...

Catalyst Pharmaceuticals posted third-quarter 2025 revenue of $148.4 million, up 17% year over year, and raised full-year guidance to...